Jingsong Wang, M.D., Ph.D. is the chief executive officer of Harbour BioMed (HBM). Before establishing HBM, Dr. Wang served as the head of China research and development center and the head of translational medicine for the Asia Pacific region at Sanofi.
Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including director of discovery medicine and clinical pharmacology and global program lead for multiple pre-clinical and clinical assets. Dr. Wang completed his clinical rheumatology fellowship and subsequently was an attending rheumatologist and faculty member at Brigham and Women’s Hospital and Harvard Medical School in Boston. Dr. Wang earned a doctor of philosophy degree in molecular pharmacology from China Pharmaceutical University in Nanjing, China and has also completed a molecular immunology research fellowship in the laboratory of Dr. Laurie Glimcher at the Harvard School of Public Health in Boston. Dr. Wang is an adjunct assistant professor of medicine at the University of Pennsylvania in Philadelphia. He has served on the research grant review committee at the National Natural Science Foundation of China, and as a scientific grant reviewer for the medical research council at the National Institute for Health Research, National Health Service of the United Kingdom.